Botanical species · safety record

Caesalpinia bonduc

The EFSA Compendium of Botanicals holds 6 constituent measurements and 2 adverse-effect records for Caesalpinia bonduc. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Caesalpinia bonduc (L.) Roxb.

6Constituent measurements
2Safety records
3Cited sources
0Licensed products (Canada)

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

  • Alkaloids1
  • Bonducellpin c1
  • Cardiac glycosides1
  • Coumarins1
  • Furan derivatives1
  • Tannins1

Plant parts

  • Leaves4
  • Roots and other underground parts4

Preparations

  • Solvent extraction8

Effect types

  • Endocrine2

Target tissues

  • Uterus2

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
AlkaloidsLeavesSolvent extractionPhytochemical screeningResolve DOI
Bonducellpin cRoots and other underground partsSolvent extractionNuclear Magnetic Resonance (NMR)Resolve DOI
Cardiac glycosidesLeavesSolvent extractionPhytochemical screeningResolve DOI
CoumarinsLeavesSolvent extractionPhytochemical screeningResolve DOI
Furan derivativesRoots and other underground partsSolvent extractionNuclear Magnetic Resonance (NMR)Resolve DOI
TanninsLeavesSolvent extractionPhytochemical screeningResolve DOI

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

EffectTarget tissuePlant partPreparationTest organismTest typeSource
EndocrineUterusRoots and other underground partsSolvent extractionRat (as animal)Reproduction toxicityNo resolvable identifier
EndocrineUterusRoots and other underground partsSolvent extractionRat (as animal)Reproduction toxicityNo resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Peter, SR., Tinto, WF., McLean, S., Reynolds, WF., Yu, M. Bonducellpins A-D, new cassane furanoditerpenes of Caesalpinia bonduc. JOURNAL OF NATURAL PRODUCTS, 1997, vol. 60, no. 12, p. 1219-1221. DOI
  2. Sivasankari, K., Janaky, S., Sekar, T. Evaluation of phytochemicals in select medicinal plants of the Caesalpinia species. Indian journal of science and technology, 2010, vol. 3, no. 12, p. 1118-1121. DOI
  3. Sukhdev, K.A., Dhondiram, M.Y., Khalure Pallavi, R., Balasaheb, C.N. Antifertility activity of root bark of Caesalpinia bonduc Linn. Roxb.in female albino rats. Pharmacologyonline, 2011, vol. 3, p. 34-41.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue